Kutatási jelek – Signal Engine

• Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis — Myelofibrosis
• Case Report: Small bowel metastasis from esophageal squamous cell carcinoma: a case series and systematic review of clinical characteristics, tropism, and survival outcomes — Esophageal cancer
• FDA Grants Fast Track Designation to BBO-11818 in KRAS+ Pancreatic Cancer — Pancreatic cancer
• Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT — NSCLC
• Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors. — Hepatocellular carcinoma
• Perioperative immunochemotherapy for resectable gastric or gastroesophageal junction cancer: a meta-analysis of efficacy and safety from randomized trials — Gastric cancer
• Risk factors for postoperative intensive care unit admission after minimally invasive esophagectomy following neoadjuvant chemoimmunotherapy in patients with esophageal squamous cell carcinoma: a retrospective cohort study — Esophageal cancer
• Presumptive Extra-Skeletal Ewing Sarcoma of the Jejunum with Disseminated Metastases — Gastrointestinal stromal tumor
• Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma — Leiomyosarcoma
• Advances in ferroptosis mechanisms and therapeutic potential in head and neck squamous cell carcinoma — Head and neck squamous cell carcinoma
• Study Tracks Early Adoption of Liver Histotripsy Treatment — Colorectal cancer
• Acute myeloid leukemia increasingly impacting older adults globally — Acute myeloid leukemia
• Case Report: The role of nodal staging in periocular Merkel cell carcinoma — lessons from three cases — Merkel cell carcinoma
• Blood test shows promise for detecting breast cancer recurrence: Study — Breast cancer
• Next-generation osteosarcoma models for precision medicine — Osteosarcoma
• Deciphering the Genomic Landscape of Oropharyngeal Squamous Cell Carcinoma: Distinct Mutation Patterns in Disease — Head and neck squamous cell carcinoma
• Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL) — Diffuse large B-cell lymphoma
• Targeting TROP2 in drug‑tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non‑small‑cell lung cancer — NSCLC
• Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities — Head and neck squamous cell carcinoma
• HGF/c-Met Signaling induces Glutamine Metabolism in Head and Neck Squamous Cell Carcinoma via MAPK/ERK-Dependent Induction of GLS-1 — Head and neck squamous cell carcinoma